Revising Adult RSV Policy: US CDC Moves Toward Risk-Based Vaccine Recommendation

The unpopular shared clinical decision-making policy for RSV vaccines in adults age 60 and older should be replaced by risk-based criteria in people age 60-74 and a universal age-based recommendation at 75 and older, the CDC’s Advisory Committee on Immunization Practices agrees.

RSV Vaccine
The ACIP work group said to recommend GSK's RSV vaccine for adults age 60-74 at increased risk of severe disease. • Source: Shutterstock

More from Vaccines

More from Pink Sheet